These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10808252)

  • 1. How BCG led to the discovery of immunostimulatory DNA.
    Tokunaga T; Yamamoto T; Yamamoto S
    Jpn J Infect Dis; 1999 Feb; 52(1):1-11. PubMed ID: 10808252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA.
    Lee KW; Jung J; Lee Y; Kim TY; Choi SY; Park J; Kim DS; Kwon HJ
    Mol Immunol; 2006 May; 43(13):2107-18. PubMed ID: 16442622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.
    Yamamoto S; Yamamoto T; Nojima Y; Umemori K; Phalen S; McMurray DN; Kuramoto E; Iho S; Takauji R; Sato Y; Yamada T; Ohara N; Matsumoto S; Goto Y; Matsuo K; Tokunaga T
    Jpn J Infect Dis; 2002 Apr; 55(2):37-44. PubMed ID: 12082305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Up-to-date understanding of tuberculosis immunity].
    Mitsuyama M; Akagawa K; Kobayashi K; Sugawara I; Kawakami K; Yamamoto S; Okada Z
    Kekkaku; 2003 Jan; 78(1):51-5. PubMed ID: 12683337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs?
    Verfaillie T; Cox E; Goddeeris BM
    Vet Immunol Immunopathol; 2005 Jan; 103(1-2):141-51. PubMed ID: 15626469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides.
    Zelenay S; Elías F; Fló J
    Eur J Immunol; 2003 May; 33(5):1382-92. PubMed ID: 12731065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model.
    Bertin S; Anjuere F; Gavelli A; Baque P; Soilihi BK; Brossette N; Loubat A; Pierrefite-Carle V
    Int J Mol Med; 2008 Mar; 21(3):309-15. PubMed ID: 18288378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro.
    Wattrang E; Berg M; Magnusson M
    Vet Immunol Immunopathol; 2005 Sep; 107(3-4):265-79. PubMed ID: 15955566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of cationic lipid complexed with immunostimulatory DNA.
    Rudginsky S; Siders W; Ingram L; Marshall J; Scheule R; Kaplan J
    Mol Ther; 2001 Oct; 4(4):347-55. PubMed ID: 11592838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its effect on immunostimulatory activity.
    Rattanakiat S; Nishikawa M; Funabashi H; Luo D; Takakura Y
    Biomaterials; 2009 Oct; 30(29):5701-6. PubMed ID: 19604576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Augmentation of the immunostimulatory effects of plasmid DNA by incorporation of human CpG-oligodeoxynucletide].
    Xu H; Deng Y; Wang S; Guo F; Lu R; Ruan L
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(7):492-5. PubMed ID: 12133524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs.
    Yew NS; Zhao H; Wu IH; Song A; Tousignant JD; Przybylska M; Cheng SH
    Mol Ther; 2000 Mar; 1(3):255-62. PubMed ID: 10933941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.